Roche has said it will spend $50bn on manufacturing and research and development in the US, becoming the latest pharmaceutical company to promise greater investment in the face of potential tariffs on the sector.
The Swiss drug and diagnostics company will make the investment over the next five years, forecasting that it would create 1,000 jobs at Roche and 12,000 in total including construction.
Chief executive Thomas Schinecker stressed that the company already had a large R&D and manufacturing base in the US. In 2009, it acquired US biotech Genentech for $47bn.
您已阅读22%（571字），剩余78%（1994字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。